Arbutus Biopharma (ABUS) vs MoonLake Immunotherapeutics (MLTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
MoonLake Immunotherapeutics (MLTX) has outperformed Arbutus Biopharma (ABUS) over the past year, gaining 16.1% versus a gain of 0.0%. Over five years, MLTX leads with a +8.6% price change compared with +5.1% for ABUS. MoonLake Immunotherapeutics is the larger company by market cap ($916.6 million vs $657.6 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | MLTX |
|---|---|---|
| Share price | $4.29 | $10.77 |
| Market cap | $657.55M | $916.60M |
| 1-day change | -4.24% | -1.64% |
| YTD return | -10.81% | -18.29% |
| 1-year return | 0.00% | +16.06% |
| 5-year return | +5.15% | +8.57% |
| P/E ratio (TTM) | 5.43 | — |
| EPS (TTM) | $0.79 | $-3.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.45 | $23.29 |
| 52-week low | $3.50 | $8.80 |
| Distance from 52-week high | -21.28% | -53.76% |
| Average volume | 4.65M | 1.43M |
| Shares outstanding | 153.28M | 85.11M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MLTX has outperformed ABUS by 16.1 percentage points over the past year.
ABUS vs MLTX FAQ
Which is bigger, Arbutus Biopharma or MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics (MLTX) is larger, with a market capitalization of $916.60M compared with $657.55M for Arbutus Biopharma (ABUS).
Which stock has performed better over the past year, ABUS or MLTX?
MLTX returned +16.06% over the past 12 months, compared with 0.00% for ABUS (price return, excluding dividends). Past performance does not predict future results.
Are Arbutus Biopharma and MoonLake Immunotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.